SG10201914135TA - Psychotropic agents and uses thereof - Google Patents
Psychotropic agents and uses thereofInfo
- Publication number
- SG10201914135TA SG10201914135TA SG10201914135TA SG10201914135TA SG10201914135TA SG 10201914135T A SG10201914135T A SG 10201914135TA SG 10201914135T A SG10201914135T A SG 10201914135TA SG 10201914135T A SG10201914135T A SG 10201914135TA SG 10201914135T A SG10201914135T A SG 10201914135TA
- Authority
- SG
- Singapore
- Prior art keywords
- amisulpride
- pharmaceutical composition
- serotonin
- individually
- dopamine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
- C07C317/36—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662427062P | 2016-11-28 | 2016-11-28 | |
US201762508263P | 2017-05-18 | 2017-05-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201914135TA true SG10201914135TA (en) | 2020-02-27 |
Family
ID=62195369
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201914135TA SG10201914135TA (en) | 2016-11-28 | 2017-11-28 | Psychotropic agents and uses thereof |
Country Status (11)
Country | Link |
---|---|
US (8) | US10259786B2 (ko) |
EP (1) | EP3544606B1 (ko) |
JP (1) | JP6968899B2 (ko) |
KR (1) | KR102274338B1 (ko) |
CN (2) | CN110248655B (ko) |
AU (2) | AU2017364899B2 (ko) |
BR (1) | BR112019010127A2 (ko) |
ES (1) | ES2908949T3 (ko) |
MA (1) | MA46901A (ko) |
SG (1) | SG10201914135TA (ko) |
WO (1) | WO2018098497A1 (ko) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11377421B2 (en) * | 2016-11-28 | 2022-07-05 | Lb Pharmaceuticals Inc. | Psychotropic agents and uses thereof |
WO2018213813A2 (en) * | 2017-05-18 | 2018-11-22 | Lb Pharmaceuticals Inc. Inc. | Psychotropic agents and uses thereof |
SG10201914135TA (en) | 2016-11-28 | 2020-02-27 | Lb Pharmaceuticals Inc | Psychotropic agents and uses thereof |
CN110790693A (zh) * | 2018-08-02 | 2020-02-14 | 北京万全德众医药生物技术有限公司 | 一种(s)(-)-氨磺必利的制备方法 |
CA3217877A1 (en) * | 2021-05-18 | 2022-11-24 | Lb Pharmaceuticals Inc. | Psychotropic agents and uses thereof |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2415099A1 (fr) * | 1978-01-20 | 1979-08-17 | Ile De France | Nouveaux derives de 4-amino-5-alkylsulfonyl ortho-anisamides, leurs procedes de preparation et leur application comme psychotropes |
US4210660A (en) * | 1978-12-20 | 1980-07-01 | Yamanouchi Pharmaceutical Co., Ltd. | Benzamide derivatives |
US4772630A (en) | 1984-11-23 | 1988-09-20 | Ciba-Geigy Corp. | Benzamides and their salts |
FR2678266A1 (fr) * | 1991-06-28 | 1992-12-31 | Delagrange Laboratoires | Nouveaux derives de 2-hydroxy 4-amino 5-ethylsulfonyl benzamide utiles comme anxiolytiques. |
AU2351895A (en) * | 1994-04-28 | 1995-11-29 | Yamanouchi Pharmaceutical Co., Ltd. | N-(3-pyrrolidinyl)benzamide derivative |
US5606482A (en) * | 1995-04-14 | 1997-02-25 | Lucent Technologies Inc. | Solid state circuit breaker |
FR2753376B1 (fr) | 1996-09-18 | 1998-10-16 | Synthelabo | Compositions pharmaceutiques comprenant de l'amisulpride et leurs applications therapeutiques |
US6169094B1 (en) | 1998-07-14 | 2001-01-02 | Sanofi-Synthelabo | Compositions of (S) (-)-amisulpride |
WO2008050341A2 (en) | 2006-10-25 | 2008-05-02 | Ramot At Tel-Aviv University Ltd | Novel psychotropic agents having glutamate nmda activity |
WO2012062697A1 (en) | 2010-11-08 | 2012-05-18 | Novartis Ag | Combination therapy for type 1 diabetes |
US20150018360A1 (en) * | 2011-09-13 | 2015-01-15 | Biomed Valley Discoveries, Inc. | Compositions and methods for treating metabolic disorders |
CN102807516A (zh) * | 2012-08-16 | 2012-12-05 | 四川省百草生物药业有限公司 | 氨磺必利的中间体及利用该中间体制备氨磺必利的方法 |
SG10201914135TA (en) * | 2016-11-28 | 2020-02-27 | Lb Pharmaceuticals Inc | Psychotropic agents and uses thereof |
WO2018213813A2 (en) | 2017-05-18 | 2018-11-22 | Lb Pharmaceuticals Inc. Inc. | Psychotropic agents and uses thereof |
MX2020005518A (es) | 2017-12-05 | 2020-11-06 | Sunovion Pharmaceuticals Inc | Mezclas no racemicas y usos de las mismas. |
-
2017
- 2017-11-28 SG SG10201914135TA patent/SG10201914135TA/en unknown
- 2017-11-28 EP EP17873556.9A patent/EP3544606B1/en active Active
- 2017-11-28 AU AU2017364899A patent/AU2017364899B2/en active Active
- 2017-11-28 US US15/824,966 patent/US10259786B2/en active Active
- 2017-11-28 MA MA046901A patent/MA46901A/fr unknown
- 2017-11-28 WO PCT/US2017/063529 patent/WO2018098497A1/en unknown
- 2017-11-28 JP JP2019548535A patent/JP6968899B2/ja active Active
- 2017-11-28 ES ES17873556T patent/ES2908949T3/es active Active
- 2017-11-28 BR BR112019010127A patent/BR112019010127A2/pt unknown
- 2017-11-28 KR KR1020197018269A patent/KR102274338B1/ko active IP Right Grant
- 2017-11-28 CN CN201780084938.8A patent/CN110248655B/zh active Active
- 2017-11-28 CN CN202010079440.6A patent/CN111233731B/zh active Active
-
2018
- 2018-02-14 US US15/896,851 patent/US10167256B2/en active Active
-
2019
- 2019-04-15 US US16/383,933 patent/US20200079734A1/en not_active Abandoned
- 2019-09-05 US US16/561,829 patent/US10689338B2/en active Active
- 2019-09-05 US US16/561,767 patent/US11040943B2/en active Active
-
2021
- 2021-06-21 US US17/304,409 patent/US11713295B2/en active Active
-
2023
- 2023-06-15 US US18/335,877 patent/US20240158347A1/en active Pending
- 2023-10-05 AU AU2023241329A patent/AU2023241329A1/en active Pending
- 2023-12-19 US US18/389,711 patent/US20240150283A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20180170868A1 (en) | 2018-06-21 |
US20240150283A1 (en) | 2024-05-09 |
MA46901A (fr) | 2019-10-02 |
KR20190086536A (ko) | 2019-07-22 |
US20180155282A1 (en) | 2018-06-07 |
AU2017364899B2 (en) | 2023-07-06 |
US20240158347A1 (en) | 2024-05-16 |
ES2908949T3 (es) | 2022-05-04 |
CN111233731A (zh) | 2020-06-05 |
EP3544606A4 (en) | 2019-12-18 |
US20220144770A1 (en) | 2022-05-12 |
CN110248655A (zh) | 2019-09-17 |
WO2018098497A1 (en) | 2018-05-31 |
US10167256B2 (en) | 2019-01-01 |
EP3544606A1 (en) | 2019-10-02 |
JP2019535837A (ja) | 2019-12-12 |
JP6968899B2 (ja) | 2021-11-17 |
US11040943B2 (en) | 2021-06-22 |
US20200079734A1 (en) | 2020-03-12 |
US20200055818A1 (en) | 2020-02-20 |
EP3544606B1 (en) | 2022-03-09 |
KR102274338B1 (ko) | 2021-07-06 |
AU2023241329A1 (en) | 2023-10-26 |
CN111233731B (zh) | 2021-05-14 |
US11713295B2 (en) | 2023-08-01 |
CN110248655B (zh) | 2023-07-07 |
US10259786B2 (en) | 2019-04-16 |
US10689338B2 (en) | 2020-06-23 |
BR112019010127A2 (pt) | 2019-08-20 |
AU2017364899A1 (en) | 2019-05-30 |
US20200002277A1 (en) | 2020-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201914135TA (en) | Psychotropic agents and uses thereof | |
PH12017501140A1 (en) | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | |
MX2018011831A (es) | Antagonistas solubles de receptor de c5aa(c5ar). | |
MX2018009257A (es) | Derivados de benzimidazol como moduladores de ror-gamma. | |
MX2016010056A (es) | 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso. | |
MX2018009752A (es) | 1,2,3,-triazoles sustituidos como moduladores de nmda selectivos de nr2b. | |
WO2017177004A8 (en) | Tertiary amides and method of use | |
BR112019001768A2 (pt) | moduladores do receptor de spiro-lactamas nmda e usos dos mesmos | |
BRPI0706726B8 (pt) | benzimidazóis 2-substituídos como modulares seletivos de receptor de andrógeno (sarms), composição farmacêutica que os compreende e processo para preparar | |
BR112016007016A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, método para tratamento sintomático do comprometimento cognitivo na demência, e, composição farmacêutica | |
PH12016501619A1 (en) | Substituted fused heterocycles as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders | |
MY198113A (en) | Piperidine cxcr7 receptor modulators | |
MX2016009581A (es) | Derivados de 6-fenil- o 6-(piridin-3-il) indazol y metodos de uso. | |
MX2017009405A (es) | Compuestos de tipo ergolina y usos de estos. | |
PH12017501280A1 (en) | Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators | |
MX2017000183A (es) | Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides. | |
MX2018002446A (es) | Compuestos heterociclicos fusionados como moduladores s1p. | |
MX2020011986A (es) | Composiciones que comprenden glucosa y hemicelulosa y su uso. | |
MX2016009621A (es) | Derivados de fur0-3-carboxamida y metodos de uso. | |
NZ734400A (en) | Amide compounds as 5-ht4 receptor agonists | |
MX364104B (es) | Moduladores del receptor cxcr7. | |
NZ737892A (en) | Muscarinic m1 receptor positive allosteric modulators | |
WO2018213813A8 (en) | Psychotropic agents and uses thereof | |
PE20160842A1 (es) | Piperidiniltetrahidroquinolinas sustituidas | |
MX2016008898A (es) | Antagonistas selectivos de nr2b. |